Esperion Therapeutics Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a research note issued on Saturday. They currently have a $30.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $64.00. Stifel Nicolaus’ price objective would indicate a potential upside of 148.96% from the stock’s previous close.
A number of other equities analysts also recently issued reports on the company. Chardan Capital reaffirmed a “neutral” rating and issued a $12.50 price target on shares of Esperion Therapeutics in a report on Saturday. Credit Suisse Group AG upped their price target on Esperion Therapeutics and gave the company an “underperform” rating in a report on Friday. Zacks Investment Research raised Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Wednesday, October 5th. Barclays PLC set a $13.00 price target on Esperion Therapeutics and gave the company a “hold” rating in a report on Wednesday, August 31st. Finally, Vetr downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 price target for the company. in a report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $26.08.
Esperion Therapeutics (NASDAQ:ESPR) traded down 7.38% during trading on Friday, hitting $12.05. 586,802 shares of the stock traded hands. The firm’s 50-day moving average is $12.34 and its 200-day moving average is $13.96. Esperion Therapeutics has a 12 month low of $9.58 and a 12 month high of $30.41. The stock’s market cap is $271.73 million.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.16. During the same period last year, the company earned ($0.55) earnings per share. On average, analysts forecast that Esperion Therapeutics will post ($3.37) EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. Quantitative Investment Management LLC acquired a new stake in Esperion Therapeutics during the second quarter worth approximately $111,000. Advisor Group Inc. acquired a new stake in Esperion Therapeutics during the second quarter worth approximately $140,000. Stifel Financial Corp increased its stake in Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares during the period. Rhumbline Advisers increased its stake in Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,657 shares during the period. Finally, ProShare Advisors LLC increased its stake in Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 238 shares during the period. Hedge funds and other institutional investors own 65.22% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.